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Upon entry into the central nervous system (CNS),
serum insulin-like growth factor-1 (IGF-I) modulates
neuronal growth, survival, and excitability. Yet
mechanisms that trigger IGF-I entry across the
blood-brain barrier remain unclear. We show that
neuronal activity elicited by electrical, sensory, or
behavioral stimulation increases IGF-I input in acti-
vated regions. Entrance of serum IGF-I is triggered
by diffusible messengers (i.e., ATP, arachidonic
acid derivatives) released during neurovascular
coupling. These messengers stimulate matrix metal-
loproteinase-9, leading to cleavage of the IGF bind-
ing protein-3 (IGFBP-3). Cleavage of IGFBP-3 allows
the passage of serum IGF-I into the CNS through
an interaction with the endothelial transporter
lipoprotein related receptor 1. Activity-dependent
entrance of serum IGF-I into the CNS may help to
explain disparate observations such as proneuro-
genic effects of epilepsy, rehabilitatory effects of
neural stimulation, and modulatory effects of blood
flow on brain activity.
INTRODUCTION
The blood-brain barriers (BBB) located at brain vessels and
choroid plexuses regulate passage of blood constituents into
the brain parenchyma and cerebrospinal fluid (CSF), respectively
(Abbott et al., 2010). Once considered an almost impermeable
barrier for serum proteins, it is now apparent that many circu-
lating hormones and growth factors can cross the BBB through
specific transport mechanisms that usually involve their cognate
receptors (Banks, 2006). However, the physiological significance
of this blood-to-brain traffic of hormones and growth factors
remains uncertain.834 Neuron 67, 834–846, September 9, 2010 ª2010 Elsevier Inc.Insulin-like growth factor I (IGF-I), a peptide with ample neuro-
protective activity (Russo et al., 2005), is one of the growth
factors found to enter the brain from the circulation (Pardridge,
1993; Carro et al., 2000; Pulford and Ishii, 2001; Reinhardt and
Bondy, 1994). Circulating IGF-I is produced mostly by the liver
and is an important mediator of growth hormone actions in
body growth and tissue remodeling. In addition, serum IGF-I
shows a wide neuroactive profile that hints to an important role
in brain homeostasis. Thus, blood-borne IGF-I modulates brain
vessel growth (Lopez-Lopez et al., 2004), adult neurogenesis
(Aberg et al., 2000), neuronal excitability (Nun˜ez et al., 2003), or
even cognitive function (Trejo et al., 2007). Collectively, these
observations provide a strong rationale for the need of circu-
lating IGF-I to cross the BBB. Notably, the BBB architecture is
well suited to transport serum IGF-I into the brain; both brain
vessels and glial end-feet surrounding them express IGF-I
receptors (Garcı´a-Segura et al., 1991). If IGF-I is transferred by
endothelial cells into the perivascular space, surrounding glial
end-feet from astrocytes, able to endocytose IGF-I (Auletta
et al., 1992), could transfer IGF-I to adjacent neurons through
trans-endocytosis or a related process. Indeed, while upon
binding to its membrane receptor IGF-I is internalized andmostly
degraded (Geary et al., 1989), several cell types can translocate
intact IGF-I to other cell compartments or even export it outside
the cell (Zapf et al., 1994).
The choroid plexus epithelium at the blood-CSF interface also
expresses high levels of IGF-I receptors (Marks et al., 1991).
In previous work we found that increases in systemic IGF-I
led to increased passage into the CSF through a mechanism
involving the multicargo protein transporter low-density lipopro-
tein receptor related protein 2 (LRP2) located in this sealed
epithelium (Carro et al., 2000, 2005). Therefore, a tonic transfer
of serum IGF-I into the CSF may be explained by physiological
oscillations in blood IGF-I levels (Carro et al., 2000). However,
serum IGF-I levels usually remain very steady. Thus, a mecha-
nism involving regulated passage of serum IGF-I may also
coexist with this tonic input. A possible regulatory mechanism
independent of changes in serum IGF-I levels may be activity
driven.
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Activity-Dependent Entrance of Serum IGF-IBrain activity dictates transfer of oxygen and nutrients from the
circulation into activated regions through a ‘‘neurovascular
coupling’’ process described long ago (Roy and Sherrington,
1890). This process recruits all the cellular components of
the neurovascular unit, with astrocytes serving an important
intermediary role between neuronal activation and endothelial
transport of oxygen and glucose (Zonta et al., 2003). Although
the intracellular pathways involved in neurovascular coupling
are not fully understood, a wealth of data indicate that diverse
mediators released in response to neuronal glutamate (arachi-
donic acid derivatives, ATP, etc.) influence the microcirculation,
allowing local increased passage of glucose and other nutrients
through brain endothelial cells.
IGF-I in blood travels as a complex with an insulin-like binding
protein 3 (IGFBP-3) and an ‘‘acid labile subunit’’ chaperone that
regulates availability to target tissues by regulated release of
IGF-I. Although the details of the trans-endothelial transport of
IGF-I are not known, the tertiary complex probably tethers/asso-
ciates to blood vessels to deliver IGF-I to endothelial cells after
cleavage of IGFBP-3 by proteases. IGFBP-3 associates to the
extracellular matrix and to membrane proteins such as LRP1.
This membrane cargo-transporter mediates transcytosis of
ligands across brain endothelial cells and has been postulated
to be a cellular receptor for IGFBP-3 (Huang et al., 2003). LRP1
is abundantly expressed in brain endothelium and interacts
with the insulin receptor (Bilodeau et al., 2009), which is closely
related to the IGF-I receptor. Altogether, these characteristics
make LRP-1 an attractive candidate to serve as a targeting
platform for the circulating IGF-I/IGFBP-3 complex.
In the present work we explored whether brain activity
modulates entrance of serum IGF-I and possible mechanisms
involved. We observed that serum IGF-I input to the brain is
regulated by an activity-driven process that includes changes
in BBB permeability to serum IGF-I. This process is initiated by
the release of glutamate at active regions. Thereafter, twoparallel
processes are set in motion: vasodilation to increase local
availability of serum IGF-I and increased activity of matrix
metalloprotease 9 (MMP9), an IGFBP3protease already reported
to be released in response to neuronal activity (Michaluk and
Kaczmarek, 2007). The combined action of these two processes
result in increased local availability of free serum IGF-I that is
transcytosed through an LRP1-dependent mechanism.
RESULTS
Neuronal Activity Stimulates Uptake of Serum IGF-I
To assess mechanisms by which IGF-I might penetrate the
BBB in response to neuronal activity, we used a combination
of experimental approaches. First, we placed a stimulating elec-
trode in the inferior cerebellar peduncle of rats receiving a bolus
injection of human recombinant IGF-I (hIGF-I; 10 mg/100 g) in the
carotid artery immediately before stimulation. By using a human-
specific IGF-I ELISA, we distinguished between exogenous and
endogenous (rat brain) IGF-I. As previously documented (Carro
et al., 2000), hIGF-I was detected in different brain regions after
systemic delivery. However, electrical stimulation (15 min, 5 Hz)
of the cerebellar peduncle elicited an additional significant
increase in cerebellar hIGF-I levels (Figure 1A). Nonstimulatedregions such as the cerebral cortex did not show differences
between stimulated and sham-stimulated animals (Figure 1A).
To assess whether systemic IGF-I accumulates in active brain
areas regardless of region and type of stimulus, we activated
the rat somatosensory cortex by unilateral whisker stimulation
(60 min, 2 or 5 Hz). As seen in Figure 1B, stimulation of the
vibrissae at 2 Hz effectively activated cortical somatosensory
neurons, whereas at 5 Hz stimulation was dumped (Figure 1B,
inset) because of neuronal desensitization (Chung et al., 2002).
Accordingly, only stimulation of the whiskers at 2 Hz increased
hIGF-I in somatosensory cortex as compared to animals
stimulated at 5 Hz or sham-stimulated animals (Figure 1B).
Frequency-dependent uptake of IGF-I by the brain correlates
with frequency-dependent changes in cerebral blood flow in
the barrel cortex during whisker stimulation (see below). These
observations further confirmed that entrance of systemic IGF-I
is regulated by neuronal activity. A region unrelated to the stim-
ulation site such as the olfactory bulb, which had relatively high
levels of hIGF-I after systemic injection, did not show stimulus-
dependent increases in hIGF-I (not shown). Local IGF-I synthesis
was not modified by stimulation; IGF-I mRNA levels in the
stimulated somatosensory cortex did not differ from those in
the unstimulated side (Figure S1A available online). Further, the
IGF-I receptor was more activated in the stimulated than in
the nonstimulated somatosensory cortex, as determined by
increased levels of the Tyr-phosphorylated form of the receptor
(Figure 1C). The latter confirms increased IGF-I input in the
stimulated area.
We next assessed whether natural alterations in brain activity
patterns, resulting from normal behavioral patterns, regulate
IGF-I entry into the CNS. Mice submitted to a brief episode
(2 hr) of environmental enrichment including multiple sensori-
motor stimuli and increased social engagement, showed a
60% increase in hippocampal IGF-I levels compared to animals
staying in their normal cages (Figure 1D). In addition, phosphor-
ylation levels of hippocampal IGF-I receptor were significantly
higher after environmental enrichment (Figure 1E). Thus, IGF-I
input to this brain area appears augmented by environmental
enrichment.
As systemic administration of IGF-I modulates basal neuronal
excitability (Nun˜ez et al., 2003), we determined whether IGF-I
also influences neuronal output in stimulated brain areas. Infu-
sion of the IGF-I receptor antagonist PPP in the somatosensory
cortex during unilateral tactile stimulation of the whiskers signif-
icantly reduced neuronal activation in this area. Under control
conditions, whisker deflections (20 ms duration) induced spike
firing in the primary somatosensory cortex of 2.9 spikes/stimulus
(Figure 1F). However, intracortical application of PPP (2.5 mM)
reduced cortical responses to 2.2 spikes/stimulus 15 min after
application (p = 0.005) and to 1.9 spikes/stimulus 30 min later
(Figure 1F, lower panel; n = 19 cells; p = 0.004). These results
strongly suggest that IGF-I input into active brain regions has
a functional impact.
Activity-Dependent Entrance of Serum IGF-I across
Brain Vessels
Albeit at lower levels, nonstimulated brain areas also accumulate
hIGF-I after intracarotid injection (i.e., cortex in Figure 1A).Neuron 67, 834–846, September 9, 2010 ª2010 Elsevier Inc. 835
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Figure 1. Active Brain Areas Accumulate Systemic IGF-I
(A) Electrical stimulation of the rat cerebellar peduncle (black bars) increased hIGF-I levels in cerebellum, as compared to sham-stimulated rats (white bars).
Unstimulated areas such as the cerebral cortex did not show differences between stimulated and nonstimulated animals. Rats received hIGF-I through the
carotid artery before stimulation of the inferior cerebellar peduncle (n = 7 per group; *p < 0.05).
(B) Electrical stimulation of the rat whiskers increased hIGF-I in the contralateral somatosensory cortex in a frequency-dependent fashion. Unilateral vibrissae
stimulation at 2 Hz activates cortical somatosensory neurons, whereas at 5 Hz stimulation is dumped due to neuronal desensitization (inset shows averages
of representative vibrissae deflection responses at somatosensory cortex; n = 10; *p < 0.05). Sham: nonstimulated animals.
(C) In 2 Hz-stimulated animals, levels of pTyr IGF-IR were significantly higher in the stimulated barrel cortex than in the ipsilateral, nonstimulated side (n = 10,
**p < 0.01). Four representative animals (coded 1–4) are shown in blot. Quantitation histograms are shown after normalization with total IGF-IR levels (lower
blot). Con, control, nonstimulated side; St, stimulated side; IgGs, band corresponding to the antibody used in immunoprecipitation.
(D) Hippocampal levels of IGF-I after 2 hr of enriched housing in mice (n = 19–20).
(E) Hippocampal levels of pTyrIGF-I receptor after environmental enrichment. Four representative animals for each group are shown. Levels of pTyr IGF-I receptor
were normalized with total IGF-I receptor. Densitometric analysis of normalized western blots is shown (n = 10; Student’s t test, **p < 0.001).
(F) Infusion of the IGF-I receptor antagonist PPP in the somatosensory cortex during unilateral tactile stimulation of the whiskers reduced neuronal activation in
contralateral cortex. Upper: peristimulus time histograms of a representative S1 cortical neuron to whisker deflection (20 ms duration) in control (left) and after
15 min of PPP (right). Lower: mean tactile responses to whisker deflections in S1 cortical neurons. PPP (solid bars), but not the vehicle (empty bars), reduced
tactile responses (n = 19; **p = 0.004).
Results are mean ± SEM (indicated by error bars) in this and subsequent figures. See also Figure S1.
Neuron
Activity-Dependent Entrance of Serum IGF-IHence, we next determined whether systemic hIGF-I entered
into the brain after neuronal activation through the blood-CSF
interface (Carro et al., 2000). We assessed levels of hIGF-I in
CSF after whisker stimulation and found no changes as
compared to nonstimulated animals (Figure S1B). This sug-
gested that activity-dependent entrance of systemic hIGF-I
occurs through a different pathway. In agreement with this,836 Neuron 67, 834–846, September 9, 2010 ª2010 Elsevier Inc.when hIGF-I (5 mg/rat) was directly delivered into the CSF
(Figure S1C), no stimulus-dependent increases of hIGF-I in the
activated somatosensory cortex were seen (Figure S1D). This
also indicated that cerebrospinal fluid IGF-I does not redistribute
to active brain regions. Hence, the other possible route of
entrance of circulating IGF-I into active brain areas is the
local vasculature. Indeed, administration of digoxigenin-labeled
Figure 2. Neuronal Activation Triggers Entrance of Circulating IGF-I
(A) Panels a and b: Digoxigenin immunostaining in somatosensory cortex of whisker-stimulated rats receiving an intracarotid injection of digoxigenin-IGF-I prior to
stimulation (a); not stimulated rats (b). Note the presence of immunostaining in the stimulated side of the cortex. Dashed area indicates somatosensory cortex. No
staining is observed in nonstimulated animals. Panel c: Magnification of the square area in a (stimulated side). Neuronal-like profiles and vessels appear stained.
M1, primary motor cortex; S1BF, primary sensory cortex barrel field area. Panel d: Digoxigenin immunostaining in rat primary sensitive cortex in the area corre-
sponding to hind limbs (S1HL) after sciatic nerve stimulation. Panel e: Immunostaining with anti-digoxigenin shows a Dig-IGF-I accumulating neuron in the vicinity
of an stained vessel in the somatosensory cortex after sciatic nerve stimulation. Panel f: Magnification of the same cortical area in a different animal after sciatic
nerve stimulation. Dig-immunopositive neuron-like cells and vessels are seen. Representative animals are shown.
(B) After whisker stimulation, double immunocytochemistry with anti-digoxigenin and cell-specific markers denoted costaining of Dig-IGF-I in endothelial cells
(tomato lectin+), astrocytes (GFAP+), and neurons (b3tubulin
+) in the stimulated side. A small vessel in barrel cortex is shown. Astrocytes surrounding a large
vessel are shown.
(C) Panels a and b: Digoxigenin immunostaining in the dorsal thalamus of nonstimulated (a) and stimulated (b) rats. Panels c and d: Magnification of the square
areas in a and b. Note the increased number of stained neuron-like cells in the stimulated side. VPM, ventral postero-medial thalamus; VPL, ventral postero-lateral
thalamus; RET, reticular nucleus of the thalamus.
(D) Stimulated brain areas along thewhisker-barrrel cortex pathway accumulate Dig-IGF-I. Neuronal activation determined by c-fos staining (green) showed over-
lapping of Dig-IGF-I staining (red) with active regions within this sensory pathway. Relay areas such as the sensitive nucleus of the trigeminal nerve, the lateral
thalamus, or the primary somatosensoty cortex are shown.
See also Figure S2.
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Activity-Dependent Entrance of Serum IGF-IIGF-I (Dig-IGF-I) immediately before stimulation of the whiskers
or the sciatic nerve resulted in specific digoxigenin immunostain-
ing in the stimulated side of the somatosensory cortex
(Figure 2A). Double immunostaining with cell-specific markers
showed that Dig-IGF-I staining colocalized with brain vessels
(lectin+ cells), astrocytes (GFAP+), and neurons (b3tubulin
+)
(Figure 2B). Cells with neuronal morphology costained for digox-
igenin and IGF-I, indicating that digoxigenin remained attached
to IGF-I (Figure S2A). Nonstimulated animals did not show
immunoreactivity in somatosensory cortex (Figure 2A, panel b).
Further, Dig-IGF-I staining was also prominent in the posterio-medial thalamus (Figure 2C) contralateral to the stimulated
whisker pad. Because this thalamic relay is within the whisker-
cortex pathway, this suggests a spatial overlap between acti-
vated areas and IGF-I uptake. In this regard, neuronal activation
determined by c-fos immunoreactivity showed overlapping of
Dig-IGF-I staining with active brain regions within this sensory
pathway such as the sensitive nucleus of the trigeminal nerve,
the lateral thalamus, and the primary somatosensory cortex
(Figure 2D). Electron microscopy analysis combined with immu-
nogold labeling confirmed the presence of Dig-IGF-I in various
cell compartments of brain vessels and neurons (Figure 3).Neuron 67, 834–846, September 9, 2010 ª2010 Elsevier Inc. 837
Figure 3. Systemically Injected Dig-IGF-I
Localizes in Barrel Cortex Endothelial Cells
and Neurons of Vibrissae-Stimulated Rats
(A) Electron microscopy photomicrograph of a
brain endothelial cell showing immunogold stain-
ing against digoxigenin in cytoplasm, mitochon-
dria, and chromatin. Arrow: stained mitochondria
in an adjacent cell.
(B) Immunogold staining in the cell nucleus, mito-
chondria, and cytoplasm of a neuron. Inset: two
labeledmitochondria are shown. M, mitochondria;
L, lumen; BL, basal lamina.
Scale bars represent 1 mm in (A) and (B) and
500 nm in (b).
Neuron
Activity-Dependent Entrance of Serum IGF-IStaining was observed in the cell nucleus, mitochondria, and
cytoplasm.
Neuro-trophic Coupling through Activity-Dependent
Mediators
Wenext searched formechanismsunderlying activity-dependent
entrance of systemic IGF-I through the brain vasculature. We
focused on neuro-vascular coupling because it involves activity-
dependent signaling from active synapses that modulate neigh-
boring blood vessels to enhance local blood flow. As expected,
unilateral electrical stimulation of the whisker pad enhanced
regional cerebral bloodflow (CBF) in theactivatedsomatosensory
cortex (Figure 4A). Increases in CBF were frequency dependent.Figure 4. Activity-Dependent Entrance of Circulating IGF-I into the Bra
(A) Time course changes in CBF in barrel cortex during whisker stimulation. Dat
prestimulation values (10–0 min). *p < 0.05 versus Sham; #p < 0.05 versus 5 H
(B) hIGF-I in insterstitial fluid collected by microdyalisis from the somatosenso
schedule employed in these experiments is shown in the upper panel.
Infusion of TTX to inhibit neuronal activity in the somatosensory cortex of vibrissae
to inhibit vasodilation also blocked the stimulus-elicited increase in hIGF-I. Infusio
A two-way ANOVA revealed a significant interaction (F(8,26) = 3.300, p < 0.01) a
showed a significant difference between baseline and stimulation only in the stim
from sham-stimulated (#p < 0.05 by Student’s t test). Blue open circle, sham (n
triangle, stimulated+L-NAME (n = 6); diamond, stimulated+MMP9 inhibitor (n = 6
See also Figure S3.
838 Neuron 67, 834–846, September 9, 2010 ª2010 Elsevier Inc.Whereas stimulation at 2 Hz consistently raised it, at 5 Hz
only a transient increase was observed (Figure S3A). This obser-
vation linked neuronal blood flow with IGF-I entrance because
at 5 Hz no increases in hIGF-I entrance were appreciated (Fig-
ure 1B). Blood pressure, body temperature, and other systemic
parameters (PCO2, PO2, etc.) remained stable during stimulation
of the animals (Table 1). No changes were observed in CBF
at the unstimulated barrel cortex (not shown). IGF-I may act
as a vasodilator, so we determined whether intracarotid adminis-
tration of IGF-I alters CBF in somatosensory cortex of nonstimu-
lated animals and found no changes (Figure S3B).
Confirming the above observations, hIGF-I levels were signif-
icantly elevated in brain interstitial fluid collected throughin
a are averaged at 5 min intervals and represented as relative changes versus
z.
ry cortex was detectable only in whisker-stimulated animals. Experimental
-stimulated animals abrogated the increase in hIGF-I levels. Infusion of L-NAME
n of an MMP9 inhibitor also resulted in inhibition of the uptake of serum IGF-I.
nd a significant effect of time (F(2, 26) = 11.80, p < 0.001). A post-hoc Tukey’s
ulated group (p < 0.01). The stimulated group was also significantly different
= 6); red square, stimulated (n = 8); up triangle, stimulated+TTX (n = 5); down
).
Table 1. Changes in Arterial Blood Parameters and Body
Temperature at Pre- and Poststimulations
Pre Post
Mean SE Mean SE
Control
pH 7.43 0.01 7.43 0.01 n.s.
PCO2 (mmHg) 36.0 1.4 38.2 0.6 n.s.
PO2 (mmHg) 96.2 2.3 94.6 2.8 n.s.
Mean arteriyal pressure
(mmHg)
98.5 3.8 100.1 4.4 n.s.
Heat rate (bpm) 371 6.1 375 6.5 n.s.
Body temperature (C) 37.6 0.2 37.7 0.1 n.s.
2 Hz
pH 7.44 0.00 7.43 0.01 n.s.
PCO2 (mmHg) 36.3 2.5 38.0 2.4 n.s.
PO2 (mmHg) 89.9 1.7 89.7 5.2 n.s.
Mean arteriyal pressure
(mmHg)
93.2 5.9 98.5 3.0 n.s.
Heat rate (bpm) 349 5.2 358 6.1 n.s.
Body temperature (C) 37.7 0.3 37.5 0.2 n.s.
5 Hz
pH 7.44 0.01 7.42 0.01 n.s.
PCO2 (mmHg) 38.3 1.0 38.1 0.9 n.s.
PO2 (mmHg) 89.7 3.2 90.2 2.2 n.s.
Mean arteriyal pressure
(mmHg)
90.4 4.1 91.4 4.8 n.s.
Heat rate (bpm) 382 18.8 391 13.2 n.s.
Body temperature (C) 37.7 0.2 37.4 0.1 n.s.
n = 4–5. n.s., nonsignificant (paired t test).
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Activity-Dependent Entrance of Serum IGF-Ia microdialysis probe placed in the somatosensory cortex of
animals receiving vibrissae stimulation at 2 Hz (p < 0.01;
Figure 4B). With this approach we determined the role of
neuronal activity and vasodilation in activity-dependent IGF-I
uptake. Intracortical infusion of TTX to inhibit neuronal activity
(markedly reducing stimulus-induced increases in CBF, see
Figure S3C) abrogated the increase in hIGF-I levels induced
by vibrissae stimulation (Figure 4B). Similarly, infusion of the
NO synthase inhibitor L-NAME to block vasodilation (which
also results in diminished CBF after whisker stimulation, see
Figure S3C) also abrogated this increase (Figure 4B). Collec-
tively, these results indicate that both enhanced neuronal activity
and increased blood flow are necessary for activity-dependent
increases in serum IGF-I input to the brain.
Because passage of serum IGF-I through blood-brain-barrier
cells may involve all the cells forming the neurovascular unit,
we then used an in vitro system to determine whether the three
main types of cells potentially involved in this purported blood-
to-brain trafficking of IGF-I can internalize it. We found that
endothelial cells, astrocytes, and neurons internalize intact bioti-
nylated hIGF-I (bhIGF-I) after adding it to the culture medium
(Figure 5A, upper blot). Elimination of nonspecific protein binding
to the cell membrane prior to cell lysis by acid wash confirmed
that the three types of cells internalize bhIGF-I (Figure 5A, lowerblots). Further, as shown in Figure 5A, double immunostaining of
biotin-labeled IGF-I and cell-specific markers show bhIGF-I
immunoreactivity in endothelial cells (lectin+ cells), astrocytes
(GFAP+), and neurons (b3tubulin
+). We then hypothesized
that once IGF-I binds to its receptors in endothelial cells, it will
be internalized and translocated to adjacent glial end-feet
surrounding brain vessels through a transcytosis process. To
analyze this point we used a double chamber culture system
with astrocytes as a feeder layer of endothelial cells in the upper
chamber and neurons placed in the lower chamber to mimic the
BBB architecture. Under these conditions, bhIGF-I was trans-
ported from the upper (i.e., apical side or ‘‘blood side’’ of the
endothelial monolayer) to the lower (basolateral side or ‘‘brain
side’’) chamber where neurons accumulated it (Figure 5B).
Next, we determined whether IGFBP-3 modulates internaliza-
tion of IGF-I by endothelial cells. In the presence of IGFBP-3
(15 ng/ml), a weak but significant decrease in bhIGF-I endocy-
tosis by brain endothelial cell cultures was observed (Fig-
ure 5C). The modest effect of exogenous IGFBP-3 could be
due to the presence of endogenous IGFBP-3, because endothe-
lial cells produce this binding protein (Lee et al., 1999). Indeed,
IGFBP-3 was detected in the cultures (Figure 5D). To further
substantiate a role of this binding protein in internalization
of IGF-I by brain endothelial cells, we determined whether
prostate-specific antigen (PSA), an IGFBP-3 protease, affected
internalization of bhIGF-I. Addition of PSA greatly increased
internalization of bhIGF-I by endothelial cells (Figure 5C).
Because the effect was antagonized by IGFBP-3 (Figure 5C),
this further supports its involvement. Further, endocytosis of
bhIGF-I required the IGF-I receptor. Either transfection of human
endothelioma cells with a dominant-negative IGF-I receptor
(Figure 5E) or incubation of brain endothelial cells with the
IGF-I receptor antagonist PPP blocked IGF-I internalization
(Figure S4A).
Because PSA is a prostate protease unlikely to be produced
by brain cells, we searched for alternative protease(s) involved
in IGFBP-3 cleavage in brain endothelium. Among potential
candidates we chose matrix metalloproteinase-9 (MMP9).
MMP9 not only cleaves this binding protein (Figure 5F; Man˜es
et al., 1999) but is present in brain endothelium (Wang et al.,
2006) and, most significantly, is modulated by brain activity
(Michaluk and Kaczmarek, 2007). In the presence of active,
but not inactive, MMP9 (50 ng/ml), brain endothelial cells endo-
cytosed significantly more bhIGF-I. The effect was inhibited
by IGFBP-3 (p < 0.001; Figure 5C). In contrast, another metallo-
protease such as MMP8 did not increase IGF-I internaliza-
tion by endothelial cells (Figure S4B). That another IGFBP-3
protease increased basal endocytosis confirmed that endothe-
lial IGFBP-3 is interfering with bhIGF-I endocytosis in our
cultures.
To gain further insight into the mechanism underlying
transcytosis of IGF-I, we used the double chamber system
mimicking the BBB, omitting neurons in the lower chamber
to avoid IGF-I uptake. Under these conditions, bhIGF-I was
transported from the upper (i.e., apical side or ‘‘blood side’’ of
the endothelial monolayer) to the lower (basolateral side or
‘‘brain side’’) chamber, and its transport was significantly
reduced when IGFBP-3 was added to the upper chamberNeuron 67, 834–846, September 9, 2010 ª2010 Elsevier Inc. 839
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Figure 5. Mechanisms Involved in Transcytosis of IGF-I across the Blood-Brain Barrier
(A) Upper blot: Neurons (Neuro), brain endothelial cells (Endo), and astrocytes (Astro) accumulate bhIGF-I in vitro. Lower blots: After eliminatingmembrane bound
bhIGF-I with acid wash prior to cell lysis, uptake of bhIGF-I by the three types of cells was still observed. Endothelial cells appear to take upmore IGF-I than either
neurons or astrocytes, as seen after normalization with b-actin. Synthetic bhIGF-I was loaded in the right lane. Micrographs: Double immunostaining with anti-
bhIGF-I and GFAP (astrocytes), b3tubulin (neurons), and tomato lectin (endothelium) showed intracellular IGF-I staining in the three types of cells.
(B) In a double-chamber well, endothelial/astrocyte cocultures in the upper chamber transport intact bhIGF-I to the lower chamber where neurons internalize it as
evidenced by the presence of bhIGF-I in neuronal extracts. Scheme of experimental arrangement is shown.
(C) In the presence of active matrix metalloprotease 9 (MMP9a) but not inactive (MMP9i), significantly more bhIGF-I was endocytosed by endothelial cells.
IGFBP-3 inhibited this effect. A similar effect was produced by PSA. **p < 0.01 and ***p < 0.001 versus control; n = 5.
(D) IGFBP-3 is produced by endothelial cell cultures. IGFBP-3 and normal rat serum (NRS, that contains IGFBP-3) were run in parallel as controls.
(E) Human endothelioma cells transfected with a dominant-negative IGF-I receptor (DN-IGF-IR) endocytosed less bhIGF-I than mock-transfected cells. Repre-
sentative blot of two experiments done in duplicate is shown. Quantitation histograms of internalized bhIGF-I shown in the right. Western blots of cell lysates for
bIGF-I and IGF-IR/b-actin were run separately in different membranes (**p < 0.01; n = 4).
(F) IGFBP-3 is cleaved by active (MMP9a) but not inactive MMP9 (MMP9i). Western blot of IGFBP-3 after treatment with MMP9 or the vehicle. Intact recombinant
IGFBP-3 was run in the right lane.
See also Figure S4.
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Activity-Dependent Entrance of Serum IGF-I(p < 0.05; Figure 6A). Confirming the effects seen in endothelial
cell cultures, MMP9 also induced transcytosis of bhIGF-I
through endothelial-astrocyte cocultures, an effect blocked by
IGFBP-3 (p < 0.01; Figure 6A).
A key aspect of our proposal is that neuronal activation
triggers serum IGF-I transcytosis from the blood into the brain.
Glutamate released during neuronal activation signals to
surrounding astrocytes (Haydon and Carmignoto, 2006; Perea
et al., 2009) that in turn release vasoactive mediators (Iadecola
and Nedergaard, 2007; Zonta et al., 2003). Accordingly, when
glutamate (100 mM) was placed in the lower chamber (the brain
side) of endothelial-astrocyte cocultures, IGF-I transcytosis
from the upper (the blood side) to the lower chamber was greatly
stimulated (p < 0.01; Figure 6B). The stimulatory action of gluta-
mate was fully abolished by an MMP9 inhibitor, reinforcing a role840 Neuron 67, 834–846, September 9, 2010 ª2010 Elsevier Inc.for this protease in transcytosis of IGF-I (Figure 6B). Moreover,
MMP9was readily detected in endothelial cells (Figure 6C, upper
blots) and glutamate stimulated it in endothelial-astrocyte
cocultures (Figure 6C). In agreement with this, and as expected
for a protease that is stimulated by brain activity (Michaluk and
Kaczmarek, 2007), activeMMP9was increased in the stimulated
somatosensory cortex (Figure 6D).
Next, we tested various vasoactive mediators proposed to be
released in response to glutamate (Iadecola and Nedergaard,
2007). Among these, we chose those previously reported to
enhanceMMPs activity. The arachidonic acid derivatives prosta-
glandin E2 (PGE2) and 11,12 epoxyeicosatrienoic acid (EET),
together with ATP, but not NO, increased bhIGF-I endocytosis
by endothelial cells (Figure 7A). Another EET derivative, 8,9
EET, with lower vasodilatory activity (Harder et al., 1998) elicited
Figure 6. MMP9 Is Involved in Passage of Serum IGF-I across Brain Endothelium
(A) Passage of bhIGF-I through astrocytes/brain endothelial cells cocultures in double-chamber wells is modulated by IGFBP-3 andMMP9 in an opposite fashion.
bhIGF-I and IGFBP-3 were placed in the ‘‘blood’’ side (upper chamber) whereas MMP9 was placed in the ‘‘brain’’ side (lower chamber) (n = 4; *p < 0.05 and
**p < 0.01 versus lower chamber in controls).
(B) Transcytosis of bhIGF-I was stimulated by glutamate (100 mM), an effect inhibited with an MMP9 inhibitor (10 mM) (n = 7; **p < 0.01).
(C) MMP9 is present in endothelial cells (upper zymography and blot) and is stimulated by glutamate in endothelial-astrocyte cocultures (lower zymography).
Representative experiments are shown (n = 2–3). Glut, glutamate; MMPa, active synthetic MMP9 was run as a control.
(D) Active MMP9 is increased in the stimulated somatosensory cortex. Western blot of MMP9 in stimulated (stim) and unstimulated (unstim) cortex of the same
animal. Recombinant MMP9 was run in parallel.
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EET. Confirming these in vitro observations, infusion of a phar-
macological dose of PGE2 (5 mM) into the rat cerebral cortex
(0.5 mm from bregma, 1 mm depth), elicited widespread
uptake of systemic digoxigenin-labeled IGF-I in the infused
side (Figure 7B). Moreover, levels of PGE2 in stimulated
somatosensory cortex increased to 4.2 ± 0.01 pg/ml from
1.9 ± 0.01 pg/ml seen in sham-stimulated cortex (p < 0.01,
n = 5 per group). Although these levels are well below the phar-
macological doses used by us, they reinforce that local
increases in PGE2 participate in serum IGF-I transfer to the brain.
We then determined whether these mediators require MMP-9
to increase IGF-I transcytosis. In the presence of an MMP9
inhibitor (inhMMP9), in vitro transcytosis of bhIGF-I by ATP,
PGE2, or EET was abrogated (Figure 7C). As in the case of
PGE2, this inhibition was not as complete as with the other medi-
ators, and it is possible that PGE2 recruits additional IGFBP-3
proteases.
Thereafter, we confirmed that MMP9 participates in activity-
dependent uptake of serum IGF-I by the brain in vivo. Infusion
of inhMMP9 into the somatosensory cortex of whisker-stimu-
lated rats blocked the increase in brain interstitial fluid hIGF-I
elicited by vibrissae stimulation (Figure 4B). Nonspecific hemo-
dynamic responses of inhMMP9 were ruled out by infusing it
into the somatosensory cortex and determining CBF responses
to whisker stimulation (Figure S3C).We next conducted an initial characterization of intracellular
pathways involved in transfer of IGF-I in response to glutamate.
We found that addition of a Ca2+ chelator (EGTA) to the culture
medium inhibited the stimulatory action of glutamate on IGF-I
transcytosis through astrocyte-endothelial cells cocultures, sug-
gesting that the process is calcium dependent (Table 2). Coaddi-
tion of thapsigargin, an inhibitor of the ryanodine receptor that
blocks intracellular Ca2+ stores, also resulted in abrogation of
IGF-I transfer, further indicating the involvement of Ca2+ fluxes
in this process (Table 2). Next, we tested various glutamate
receptors antagonists and found that inhibition of ionotropic
AMPA/Kainate receptors with CNQX or of mGluR5 with MPEP
abrogated glutamate actions whereas NMDA and mGluR1
antagonists (AP5 and Lyly, respectively) did not alter the effect
of glutamate (Table 2). Further, inhibition of prostanoid synthesis
with the Cox inhibitor ibuprofen similarly blocked glutamate
effects. Finally, no effect on glutamate actions was seen after
inhibition of purinergic signaling via suramin (Table 2). Alto-
gether, these results indicate that non-NMDA ionotropic and
GluR5metabotropic glutamate receptors are involved in transfer
of IGF-I through astrocyte/endothelial cocultures and that pros-
tanoid synthesis is required for this effect.
In response to neuronal activation, local levels of circulating
IGF-I/IGFBP3 will increase as a result of increased local blood
flow. We postulated that this complex would interact with
LRP1/IGF-IR at endothelial cells for subsequent transcytosis ofNeuron 67, 834–846, September 9, 2010 ª2010 Elsevier Inc. 841
Figure 7. Mediators Involved in Neurovascular Coupling Modulate
Passage of Blood-Borne IGF-I across Brain Endothelium
(A) Diffusible mediators released by astrocytes during neurovascular coupling
stimulated endocytosis of bhIGF-I by brain endothelial cells. Prostaglandin E2
(PGE2), epoxyeicosatrienoic acid (EET), and ATP, but not NO (stimulated with
SNAP), enhanced IGF-I internalization. Combined addition of the three
compounds elicited a similar increase (n = 6–10).
(B) Infusion of PGE2 into the cerebral cortex (0.5 mm from bregma, 1 mm
depth) of rats previously receiving an intracarotid injection of Dig-IGF-I results
in robust digoxigenin staining in the infused side 30 min later. Note that both
the contralateral, vehicle-infused side and the brain surface of the injected
side showed low immunoreactivity attributable to local disruption of the
BBB. Three consecutive 50 mm brain sections are shown.
(C) Enhanced internalization of bhIGF-I by PGE2, EET, and ATP is inhibited by
the MMP9 inhibitor. Note that the drug alone decreases bhIGF-I internalization
to the same extent, indicating that endogenousMMP9 is required to internalize
IGF-I (n = at least 3 experiments); ***p < 0.001, **p < 0.01, and *p < 0.05 versus
control.
Table 2. Glutamate-Dependent Pathways Involved in
Transcytosis of IGF-I across Endothelial-Astrocyte Cocultures in
Double-Chamber Configuration
Treatment
IGF-I Transcytosisa
(% Glutamate)
Statistical
Significanceb
Glutamate (n = 5) 100 ± 26 -c
Glutamate + AP5 (n = 5) 73 ± 31 0.24
Glutamate + CNQX (n = 5) 55 ± 11 0.001
Glutamate + lyly (n = 5) 184 ± 120 0.33
Glutamate + MPEP (n = 3) 0.3 ± 0.19 0.0004
Glutamate + thapsigargin (n = 3) 0.2 ± 0.5 0.0003
Glutamate + EGTA (n = 3) 5.1 ± 0.4 0.0006
Glutamate + ibuprofen (n = 3) 53 ± 21 0.002
Glutamate + suramin (n = 3) 113 ± 18 0.13
aMean ± SEM
bAs compared to glutamate (Student’s t test).
cGlutamate induced a 217% ± 58% increase in IGF-I transcytosis over
controls (p = 0.02).
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we observed that LRP1 interacts with IGFBP3. LRP1 was
coimmunoprecipitated with IGFBP3 in cell extracts from endo-
thelial cultures treated with IGFBP3 (Figure 8A). LRP1 also coim-
munoprecipitated with the IGF-I receptor in brain endothelial
cells (Figure 8B). Conversely, an HA-tagged mini-LRP1 (lacking
most of the extracellular domain of LRP1) expressed in brain842 Neuron 67, 834–846, September 9, 2010 ª2010 Elsevier Inc.endothelial cells coimmunoprecipitated with IGF-IR (Figure 8C).
This suggested that the interaction between LRP1 and IGF-IR
does not involve the extracellular ligand-binding domain of
LRP1, leaving this domain free for binding of extracellular ligands
such as IGFBP3. Finally, whereas endothelial cells expressing
mini-LRP-1 internalized significantly more bhIGF-I than control
cells (Figure 8D), HCMEC-D3 endothelioma cells expressing
LRP1 siRNA internalized markedly less bhIGF-I than scramble
siRNA-transfected cells (Figures 8E and 8F). Thus, interaction
of LRP-1 with the IGF-I receptor and IGFBP-3 may target the
IGF-I/IGFBP-3 complex to the IGF-I receptor and facilitate the
subsequent transcytosis of IGF-I.DISCUSSION
The present results indicate that brain activity drives serum IGF-I
input to activated areas. This novel link between neuronal activa-
tion and localized trophic support appears to recruit processes
also involved in neurovascular coupling (Figure 8G). The fact
that similar processes participate in allocating nutrient/oxygen
supply and at the same time trophic support to active brain
regions widens the physiological significance of activity-depen-
dent processes in the brain. Importantly, these observations also
provide a regulatory mechanism for the neuroactive actions of
blood-borne IGF-I.
In line with these observations, the increases previously
observed in the number of IGF-I immunoreactive neurons in
the developing rat visual cortex after experience-dependent
neuronal activity (Ciucci et al., 2007) or after environmental
enrichment (Guzzetta et al., 2009) may be explained by localized
transfer of serum IGF-I to the brain. Also, higher brain activity
observed in human subjects with higher serum IGF-I levels
(Arwert et al., 2005) agree with these findings. Together with
recent evidence that neuronal activity increases antioxidant
defenses in neurons (Le´veille´ et al., 2010; Papadia et al., 2008),
these data provide further insight into the neuroprotective effects
of neuronal activity.
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Figure 8. The IGF-I Receptor Interacts with LRP-1 in Brain Endothelial Cells
(A) LRP-1 coimmunoprecipitates with IGFBP-3. Standard IGFBP-3 is shown in the right lane.
(B) Coimmunoprecipitation of LRP1 and IGF-I receptors in brain endothelial cells. An LRP1 band was detected only in anti-IGF-I receptor (IGF-IR) immunopre-
cipitates (IP). Sup, supernatants.
(C) IGF-I receptors (IGF-IR) in brain endothelial cells coimmunoprecipitated with an HA-tagged mini-LRP1. Both supernatants (Sup) and immunoprecipitated
pellets (IP) were assayed in an IGF-IR western blot. Controls included nontransfected cells and anti-IGF-IR immunoprecipitated fractions.
(D) Transfection of brain endothelial cells with mini-LRP1 enhanced endocytosis of bhIGF-I (**p < 0.01, n = 4).
(E and F) Transfection of the human endothelioma HCMEC-D3 with an LRP1 siRNA resulted in marked inhibition of bhIGF-I internalization. Control cultures were
transfected with a scramble shRNA sequence.
(E) Western blots of cell lysates for bIGF-I and LRP1/b-actin were run separately in different membranes. Two experiments (in duplicate) were loaded/gel.
(F) Quantitation histograms (*p < 0.05; n = 4).
(G) Proposed mechanisms involved in serum IGF-I uptake by active brain regions. Increased neuronal activaty results in increased blood flow through neurovas-
cular coupling. The resulting local vasodilation increases the amount of circulating IGF-I at the stimulated area. Neuronal activity also stimulates MMP9 activity
that releases IGF-I from IGFBP3, allowing its internalization through the BBB in an LRP1-dependent process. Increased IGF-I input in stimulated areas stimulates
neuronal activity. Through this step-wise pathway, serum IGF-I could modulate neuronal activity.
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Activity-Dependent Entrance of Serum IGF-ITranscytosis of molecules across the BBB is the most
common way to modulate the permeability of this barrier
(Banks, 2009). Neuronal activity modulates BBB permeability
through neurovascular coupling. In turn, serum IGF-I partici-
pates in brain processes where neuronal activity is involved
(synaptic plasticity, cognition, etc.). Therefore, we reasoned
that neuronal activity could influence BBB permeability to serum
IGF-I. Although activity-driven neurovascular and neuro-trophic
coupling may share common upstream mechanisms such as
vasodilation (Figure 8G), downstream mechanisms leading to
increased glucose uptake and IGF-I transfer, respectively, prob-
ably diverge. In the former case neuronal release of glutamate
leads to Ca2+ fluxes in astrocytes and subsequent release of
diffusible mediators such as NO, arachidonic acid derivatives,ATP, etc., that modulate the microcirculation. Eventually,
glucose and oxygen uptake are locally enhanced. Glucose
uptake through the BBB is increased because glucose trans-
porters are translocated to the cell membrane in response to
a signaling mechanism that is still not well characterized. In
neuro-trophic coupling, our initial observations suggest that
together with vasodilation that will increase local availability of
circulating IGF-I, glutamate release activates MMP9 in a process
that appears to recruit several but not all of the mediators
involved in vasogenic aspects of neurovascular coupling and
that also involves Ca2+mobilization. Thus, our initial in vitro phar-
macological characterization suggests that IGF-I transfer
depends on ionotropic (AMPA/kainate) and metabotropic
(mGluR5) glutamate receptors, arachidonic acid derivatives,Neuron 67, 834–846, September 9, 2010 ª2010 Elsevier Inc. 843
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Activity-Dependent Entrance of Serum IGF-Iand Ca2+ fluxes. However, more work is needed to ascertain the
cellular and molecular pathways involved. In this regard,
it should be noted that after many years of study, the mecha-
nisms underlying neurovascular coupling are still under intense
scrutiny (Shi et al., 2008).
At any rate, the present results allow us to propose an over-
view of the possible processes involved. Besides local changes
in blood flow (in vivo inhibition of NO blocks IGF-I transfer), acti-
vation of MMP9 (and other proteases?) by diverse mediators
(prostanoids, EETs, ATP) appears as the distinct characteristic
required in IGF-I transfer across the BBB. MMP9 links neuronal
activation with transfer of blood-borne IGF-I through an LRP1-
dependent process. A similar process probably takes place at
the choroid plexus, where the closely related receptor LRP2
also binds to the IGF-I receptor and actively participates
in IGF-I transcytosis (Carro et al., 2005). Thus, two parallel
processes, neurovascular coupling and neuro-trophic coupling,
are set in motion by glutamate release at active synapses.
Several questions remain open. For instance, although the
absence of changes in IGF-I mRNA synthesis after brain activa-
tion suggests that brain activity does not induce local IGF-I
synthesis, locally activated IGF-I protein translation cannot be
ruled out. This possibility would require further study. Further,
although IGF-I immunoreactivity in the nucleus of astrocytes
and neurons was already observed by us (Garcı´a-Segura et al.,
1991) and more recently confirmed in other cell types (Sehat
et al., 2010), the role that IGF-I may play in these cellular organ-
elles is still not fully understood.
Our observations also provide a mechanistic support for the
cognitive reserve hypothesis of neuroprotection. Conceivably,
neuro-trophic coupling may contribute to the beneficial effects
of an active social life and higher education on brain function
(Fratiglioni et al., 2004). Neuroprotective behaviors such as
exercise or balanced diets also favor entrance of serum IGF-I
into the brain (Carro et al., 2000; Dietrich et al., 2008), so this
neuroprotective serum growth factor may be considered a
common mediator of the beneficial effects of diverse lifestyle
factors on brain health.
These findings may help explain disparate observations such
as the proneurogenic effect of epilepsy or electroconvulsive
therapy (Kempermann, 2002), the modulatory effect of blood
flow on neuronal activity (Moore and Cao, 2008), or the rehabil-
itatory effect of neural stimulation (Kaelin-Lang, 2008). The latter
may be of particular practical impact. The unifying thread in all
these processes would be increased input of serum IGF-I to
stimulated brain regions. In the first case, enhanced neurogene-
sis after neuronal hyperactivity could be explained by the potent
neurogenic effects documented for serum IGF-I (Trejo et al.,
2008). In the second case, activity-dependent entrance of serum
IGF-I coupled to enhanced blood flow would conform to the
‘‘hemo-neural’’ hypothesis that proposes that diffusible blood-
borne messengers modulate neuronal activity (Moore and Cao,
2008). Indeed, systemic IGF-I increases neuronal excitability
(Nun˜ez et al., 2003) and levels of serum IGF-I correlate with brain
vascular activation (Arwert et al., 2005). Finally, neural stimula-
tion inducing the entrance of systemic IGF-I will in turn produce
wide beneficial effects on activated areas through the ample
neuroprotective actions of IGF-I (Carro et al., 2003). An unex-844 Neuron 67, 834–846, September 9, 2010 ª2010 Elsevier Inc.plored aspect of these observations is the angiogenic role of
serum IGF-I (Lopez-Lopez et al., 2004). As vessel formation is
regulated by tissue demand, activity-dependent uptake of
serum IGF-I through brain vessels would also impinge on vessels
themselves. Altogether, activity-dependent entrance of a serum
neuroprotective factor supports the use of neuro-rehabilitation
procedures based on targeted neuronal stimulation of damaged
areas.
EXPERIMENTAL PROCEDURES
In Vivo Procedures
Human recombinant IGF-I was administered in the carotid artery or into the
brain lateral ventricle to adult male Wistar rats prior to the stimulation proto-
cols. Drugs were directly infused into the primary somatosensory cortex. At
the end of each experiment, brains were perfused with saline and processed
for immunocytochemistry or frozen for various biochemical determinations.
For barrel cortex sampling, the brain was cut rostro-caudally until the medial
fusion of the anterior commisure (0.3 mm from bregma). Thereafter, a
2mmslice wasmade and a piece of the barrel cortex isolated through two inci-
sions perpendicular to the surface of the cortex at 4.5 and 7 mm from midline.
CSF was collected from the cisterna magna.
Stimulation Protocols
The rat inferior cerebellar peduncle was stimulated with 0.1 ms square pulses
(50–100 mA) at 5 Hz frequency. The whisker pad was stimulated with a 1 ms
square pulse (50–100 mA) with two subcutaneous electrodes located at the
dorso-anterior and caudo-posterior edges of the whisker pad. Stimulus-
evoked potentials were recorded in barrel cortex in some animals. Rat whis-
kers were also stimulated by an electronically gated air jet in 20 ms, 0.5 Hz
pulses. The sciatic nerve was stimulated by delivering pulses of 100 ms,
0.5 Hz, and 10–50 mA. For sham stimulation, electrodes were placed without
delivering any current. Behavioral stimulation of adult C57BL6J male mice
consisted of enriched housing in a large arena with toys, exercise wheels,
and 10 animals per cage.
Brain Microdialysis
A guide cannula was fixed above the barrel cortex contralateral to the stimu-
lated whisker pad of adult rats, and after rats recovered from surgery, a micro-
dialysis probe was inserted through it into the barrel cortex. The probe was
infused with artificial cerebrospinal fluid in a push-pull manner. Infusion
protocols are summarized in Figure 4B. Dialysates were collected at 60 min
intervals to determine hIGF-I levels. Cannula placement was always confirmed
by histology.
Cell Cultures and In Vitro Assays
All cultures were performed as described previously (Fernandez et al., 2007).
Coculture of endothelial cells and astrocytes to mimic BBB architecture was
performed as described by others with a double-chamber culture well (Perrie`re
et al., 2007). Formation of a sealed monolayer was confirmed by measuring
electrical resistance and retention of fluorescent dextran. In transcytosis and
internalization assays, we used biotinylated IGF-I to distinguish it from endog-
enously produced IGF-I. Cells were transfected with siRNAs, mini-LRP1, or
dominant-negative IGF-I receptor and used 48–72 hr later.
Cerebral Blood Flow Measurement
Cerebral blood flow was monitored during whisker pad stimulation with laser-
Doppler flowmetry after performing a small craniotomy over the barrel cortex.
The time constant was 0.01 s. Before and after stimulation, arterial blood gases
and pressure were monitored. Data were averaged at 5 or 20 min intervals and
represented as relative changes versus baseline.
In Vivo Recordings
After drilling a small hole in the skull over the SI cortex, unit recordings
were recorded below the brain surface via tungsten microelectrodes. Unit
Neuron
Activity-Dependent Entrance of Serum IGF-Ifiring was filtered, amplified, and fed into a computer for offline analysis.
Cortical field potentials were recorded at SI cortex, with tungsten macroelectr-
odes. Averages of the field potentials and summed peristimulus time histo-
grams were calculated from 20 stimuli. Data were compared with Student’s
paired t test.
Immunoassays
Immunocytochemical assays were performed as previously described. First
antibodies were omitted in control sections and no staining was observed
(not shown). Human and murine IGF-I levels were determined by species-
specific ELISAs as described (Trejo et al., 2007). A commercial ELISA was
used to measure PGE2 in cortical lysates.
Gel Zymography
MMP-9 activity in glutamate-treated cultures and brain samples was assessed
by gelatin zymography. Lysates were loaded under no reducing conditions
onto 10% polyacrylamide-1% gelatin gels. To reveal the gelatinolytic activity,
gels were stained with 0.25% brilliant blue and destained with 10% methanol
and 7% acetic acid.
Pre-Embedding Immunogold Labeling and EM
Brain were perfused with 0.5% glutaraldehyde/2.5% paraformaldehyde
and sections (50 mm) were immunostained with digoxigenin antibodies and
a secondary antibody conjugated to colloidal gold, enhanced with silver,
washed, postfixed with 2.5% glutaraldehyde for 20 min, washed, and post-
fixed with 1% osmium tetroxide. Immunostained sections were dehydrated
and embedded in resin. Sixty nanometer sections were cut and collected on
Formvar-coated single-slot grids, stained with uranyl acetate and lead citrate,
and examined with a FEI Tecnai Spirit electron microscope.
Quantitative PCR
IGF-I qPCR was performed as described. Equivalent amounts of isolated
total brain RNA served as template to synthesize cDNA. TaqMan probes
and primers for IGF-I and for the control housekeeping gene, rRNA 18s,
were used. IGF-I mRNA was normalized to the endogenous reference and
expressed relative to the calibrator.
Statistics
One- and two-way ANOVAs were used for overall comparisons as indicated in
the legends of the figures. Post-hoc tests included Tukey and Student’s t test.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at doi:10.1016/
j.neuron.2010.08.007.
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